Review· 2018
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.
International journal of molecular sciences
Back to all molecules
Human researchNot FDA-approved as a drug
GHK-Cu
Copper-binding tripeptide complex
Also indexed as: Copper tripeptide-1
What this evidence does not tell us
The review combines mechanistic and topical research. Topical cosmetic findings cannot be extrapolated to injection, systemic recovery or lifespan benefits.
Terms on this page
Unfamiliar word? Open this panel for simple explanations, right here.
4 glossary terms used in this profile
Terms on this page
Unfamiliar word? Open this panel for simple explanations, right here.
4 glossary terms used in this profile
Select a word to see its meaning. You can keep more than one definition open.
Definitions explain the words—not whether a molecule works or is safe. Research education only, not medical advice.
Overview
GHK-Cu is a complex of copper with the tripeptide glycyl-histidyl-lysine. The literature includes cell biology and topical skin research; those contexts must be distinguished from systemic administration.
Mechanism of action
Copper / extracellular matrix
Copper binding and interactions with cellular signaling are investigated in relation to collagen, extracellular-matrix remodeling and tissue responses. Effects depend on model, formulation and route.
A biological pathway describes a proposed or observed interaction—not necessarily a demonstrated health outcome.
Decode the terminology in our glossaryScientific evidence
How strong is the evidence?
Human evidence is still developing
- Limited evidence
- Early research
- Human researchCurrent category
- Human outcomes
Studies in people exist, but the findings may be small, narrow, mixed or still need confirmation. A hormone or cell marker is not necessarily a health benefit.
For this research: The review combines mechanistic and topical research. Topical cosmetic findings cannot be extrapolated to injection, systemic recovery or lifespan benefits.
An editorial guide—not a validated score, a percentage, a safety rating or an approval badge. Regulatory status is separate. More research does not mean fewer risks.
Cell studies
Mechanistic laboratory evidence is not separately assessed in this selected-source summary; see references and their study types.
Animal experiments
Animal evidence is not separately assessed here. Findings in animals must not be interpreted as demonstrated human benefit.
Human observational studies
Associations, biomarker studies and anecdotes cannot establish treatment causality; no observational result is used here to infer clinical effectiveness.
Human clinical trials
Small topical/cosmetic studies are discussed in the review. This does not establish systemic safety or clinical effectiveness.
Regulatory evidence
Cosmetic use is not FDA drug approval. GHK-Cu is not FDA-approved as an injectable medication; topical and injectable exposure are not interchangeable.
Potential research applications
Topical skin remodeling and extracellular-matrix biology.
These describe scientific questions, not prescribing recommendations. A research grouping does not establish combination safety or clinical effectiveness.
Explore research by health goalSafety considerations
Topical irritation or sensitivity is possible. Injectable exposure has different risks; FDA identifies aggregation, impurities and limited human safety information for injections.
This is not an exhaustive safety or contraindication list. An absence of reported harm is not proof of safety. Pregnancy, breastfeeding, cancer history, endocrine disease and concurrent medicines can materially change risk. Unregulated preparations add identity, contamination and sterility risks.
Read FDA’s compounding safety informationRegulatory status · United States
Not FDA-approved as a drug
Cosmetic use is not FDA drug approval. GHK-Cu is not FDA-approved as an injectable medication; topical and injectable exposure are not interchangeable.
Regulatory status and evidence strength are different. A nomination for compounding, a clinical-trial registration or a “research use only” label is not approval. International rules vary; consult the current regulator and product label.
Selected literature & source transparency
Matched bibliographic records confirm a publication’s identity, not the validity of every claim. Selected sources are not a systematic literature review.
Continue your own source search
These open search results, not additional verified citations. Trial registration is not evidence that a treatment works.
Three questions worth bringing to your clinician
- Which human outcomes—not just biomarkers—support this claim?
- What established options address my actual health concern?
- What do my medical history and current medicines change about the risks?
Beyond the library
Turn better questions into a thoughtful conversation.
Explore our broader health optimization approach. A library entry does not mean a molecule is offered, prescribed, or appropriate for you.
Request an Optimization Consultation
Continue to our existing activation & intake page.